Research Topics
Species | Bernard H BochnerSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgeryBradley Andrew Morganstern
Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461, USA
Health Qual Life Outcomes 9:10. 2011..Our evaluation of this measure is a prelude to a prospective comparison of quality of life outcomes of reconstructive procedures after cystectomy...
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancerBernard H Bochner
Department of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Tumors, 353 E 68th St, New York, NY 10021, USA
J Clin Oncol 24:3967-72. 2006..The goal of this study was the development of a prognostic outcomes nomogram to predict the 5-year disease recurrence risk after radical cystectomy...
Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancerBernard H Bochner
Department of Urology, Memorial Sloan-Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, 353 E 68th Street, New York, NY 10021, USA
Nat Clin Pract Oncol 3:474-5. 2006
Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patientsBernard H Bochner
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, New York, New York 10021, USA
J Urol 182:2376-80. 2009..We report our experience with this reservoir to compare complications in irradiated and nonirradiated patients...
Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiationBernard H Bochner
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 94:140-6. 2004..Evaluation of a modified right colon urinary reservoir in a heavily radiated patient population undergoing pelvic exenteration...
Optimal timing of radical cystectomy for patients with T1 bladder cancerBernard H Bochner
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Urol Oncol 27:329-31. 2009..This article reviews the various features associated with an increased risk of disease progression to provide a framework for optimizing the timing of radical cystectomy...
Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancerBernard H Bochner
Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, Kimmel Bldg, New York, NY 10021, USA
Urol Clin North Am 30:777-89. 2003..Because of the ever-increasing fiscal constraints placed on clinicians, risk-adjusted follow-up strategies are reasonable, but will require prospective evaluation to validate their appropriateness...
Gene therapy in bladder cancerBernard H Bochner
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
Curr Opin Urol 18:519-23. 2008..Several gene therapy strategies have been studied in the treatment of bladder tumors. In this review, an update of the recent outcomes of viral-based gene therapy for bladder cancer is discussed...
Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mappingBernard H Bochner
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 172:1286-90. 2004..We prospectively evaluated RC cases with transitional cell carcinoma of the bladder to determine which factors may contribute to the variability in the number of reported LNs...
Clinical outcomes of primary bladder carcinoma in situ in a contemporary seriesDaher C Chade
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 184:74-80. 2010..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experienceAtreya Dash
Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 113:2471-7. 2008..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tractMatthew D Galsky
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 69:255-9. 2007..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?Ricardo L Favaretto
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
Eur Urol 58:645-51. 2010..Questions remain regarding the oncologic safety of LRN and its relative equivalence to ORN...
Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinomaRicardo L Favaretto
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BJU Int 109:77-82. 2012....
Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancerGanesh V Raj
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 107:2167-72. 2006..However, the overall risk of recurrence is low and is not clearly associated with overall survival. The data do not support routine intraoperative frozen sections to assess ureteral involvement...
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancerDavid S Yee
Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 183:1751-6. 2010..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities...
Natural history of positive urinary cytology after radical cystectomyGanesh V Raj
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 176:2000-5; discussion 2005. 2006..Additionally, these data indicate the need for diligent evaluation for recurrent disease and potentially the role of early adjuvant therapy in patients with positive cytology after radical cystectomy...
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancerTheresa M Koppie
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer 112:2384-92. 2008..Also evaluated was whether ACCI was associated with clinicopathologic and treatment characteristics...
Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillanceWilliam Tran
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 179:96-100. 2008..However, these recurrence rates are based on statistical methodology that does not take censoring into account. We used landmark time analysis to determine whether the risk of upper tract recurrence changes over time...
Clinical outcome of primary versus secondary bladder carcinoma in situDaher C Chade
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 184:464-9. 2010..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors...
Bladder cancer as a prognostic factor for upper tract transitional cell carcinomaMichael Mullerad
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 172:2177-81. 2004..CONCLUSIONS: This study demonstrates that a history of BTCC (invasive or superficial) has an adverse effect on the prognosis of patients diagnosed with UTTCC independent of primary tumor stage...
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancerGanesh V Raj
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 177:1283-6; discussion 1286. 2007..In this study we explored the effect of this paradigm shift on progression rates and disease specific survival...
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selectionJeffrey M Holzbeierlein
Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 E. 68th Street, New York, NY 10021, USA
J Urol 172:878-81. 2004..CONCLUSIONS: In highly selected patients with invasive bladder cancer, partial cystectomy offers acceptable outcomes. Concomitant CIS and presence of metastases to regional lymph nodes predict advanced recurrence...
Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancerFernando P Secin
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Int J Urol 14:26-32. 2007..We evaluated the manner in which the LND was applied at NU, the patterns of lymph node (LN) involvement and the preoperative variables that could identify patients at high risk for lymph node metastasis (LNM)...
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomyJoseph A Pettus
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Eur Urol 53:370-5. 2008....
Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectorsEiji Kikuchi
Departments of Urology and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:4511-8. 2007..In an attempt to improve viral delivery of potentially therapeutic genes via an intravesical route, we have recently developed murine leukemia virus-based replication-competent retrovirus (RCR) vectors...
Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?Theresa M Koppie
Department of Urology, Sidney Kimmel Center for Urologic Cancer, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 107:2368-74. 2006..The goal of the current study was to determine if a threshold number of nodes exists, above which taking additional LNs has no clinical benefit...
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approachAndrew J Vickers
Department of Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 115:5460-9. 2009....
Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivityTatum V Tarin
Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Eur Urol 61:1025-30. 2012..The extent of lymphadenectomy needed to optimize oncologic outcomes after radical cystectomy (RC) for patients with regionally advanced bladder cancer (BCa) is unclear...
Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapyMatthew G Kaag
Department of Surgery, Urology Section, Memorial Sloan Kettering Cancer Center, 1275 York Ave Box 213, New York, NY 10065, USA
BJU Int 108:E272-7. 2011..To evaluate the effect of preoperative cisplatin-based chemotherapy on the regional lymph nodes of patients with bladder cancer who attain pathological T0 status in the bladder after chemotherapy followed by radical cystectomy...
Importance of node dissection in relation to neoadjuvant and adjuvant therapyWilliam C Huang
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA
J Natl Compr Canc Netw 4:1019-26. 2006....
Urachal carcinoma: contemporary surgical outcomesHarry W Herr
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 178:74-8; discussion 78. 2007..We determined surgical outcomes in a contemporary series of patients who underwent surgery for urachal carcinoma...
Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patientsOfer Yossepowitch
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 176:482-5. 2006..Further studies are warranted to assess the safety and efficacy of bacillus Calmette-Guerin instillations in critically immunocompromised patients...
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer CenterRicardo L Favaretto
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Eur Urol 58:574-80. 2010..The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious...
Radical cystectomy and lymphadenectomy for invasive bladder cancer: towards the evolution of an optimal surgical standardGanesh V Raj
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 34:110-21. 2007..This ongoing evolution in the technique of RC and pelvic lymph node dissection (PLND) may help define a new surgical standard that provides optimal benefit in patients with invasive bladder cancer...
Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrenceOfer Yossepowitch
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Urol 169:177-81. 2003....
Urinary diversion practice patterns among certifying american urologistsJonathan L Silberstein
Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York
J Urol 189:1042-7. 2013..We investigated trends in urinary diversion use and surgeon characteristics in the performance of incontinent and continent urinary diversion using American Board of Urology data...
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancerJoshua J Meeks
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Eur Urol 62:523-33. 2012..Muscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC...
Pelvic exenteration with curative intent for recurrent uterine malignanciesFady Khoury-Collado
Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 124:42-7. 2012..To evaluate the outcomes observed with pelvic exenteration with curative intent for recurrent uterine malignancies in the modern era...
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experienceS Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
Eur Urol 55:177-85. 2009..However, in a recent report from the National Cancer Database (NCDB), only 11.6% of stage III BCa patients received perioperative chemotherapy, the majority in the adjuvant setting...
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodologyAhmad Shabsigh
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
Eur Urol 55:164-74. 2009..Reporting methodology is highly variable and nonstandardized, yet surgical outcomes are utilized in clinical trial design and evaluation of healthcare provider performance...
Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinomaMichael Mullerad
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 174:741-6. 2005..CONCLUSIONS: These data provide the cellular basis for the clinical investigation of combined MMC and oncolytic HSV therapy for the treatment of bladder cancer...
Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessmentsDipen J Parekh
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:5519-27. 2006..Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy...
Prognostic significance of p27Kip1 expression in bladder cancerFarhang Rabbani
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 100:259-63. 2007....
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancerHarry W Herr
Departments of Urology (Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
J Urol 167:1295-8. 2002..Such information is important not only for the therapy and prognosis of individuals, but also for identifying those who may benefit from adjuvant chemotherapy...
Use of nomograms as predictive tools in bladder cancerAhmad Shabsigh
Division of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, 353 E. 68th Street, New York, NY 10021, USA
World J Urol 24:489-98. 2006..We summarize the current status of outcome predictive models for bladder cancer; and focus particularly on the ability of nomograms to predict disease recurrence, progression, and patient survival...
Pubovesical fistula: a rare complication after treatment of prostate cancerKazuhito Matsushita
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Urology 80:446-51. 2012....
Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancerHeiko Schoder
Department of Radiology, Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Mol Imaging Biol 14:245-51. 2012..To investigate the utility of (11)C-acetate positron emission tomography/computed tomography (PET/CT) for staging of bladder cancer and response assessment after neoadjuvant chemotherapy...
The effect of age and gender on bladder cancer: a critical review of the literatureShahrokh F Shariat
Division of Urology Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
BJU Int 105:300-8. 2010..We must strive to develop transdisciplinary collaborative efforts to provide tailored gender- and age-specific care for patients with UCB...
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladderAtreya Dash
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 107:506-13. 2006..This finding is most striking in the elderly. Better selection of patients who may safely receive cisplatin and more effective regimens devoid of cisplatin are required to optimize outcomes in this group of patients...
A plea for a uniform surveillance schedule after radical cystectomyGuido Dalbagni
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 185:2091-6. 2011..We identified the pattern of post-cystectomy surveillance recommended in the oncologic community and assessed compliance to a predetermined schedule among a small group of urologists...
Current status of establishing standards for lymphadenectomy in the treatment of bladder cancerWilliam C Huang
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Curr Opin Urol 15:315-9. 2005..Prospective, randomized trials will be needed to properly establish the extent of lymphadenectomy required to obtain such benefits...
Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinomaBehfar Ehdaie
Urology Service, Sidney Kimmel Center for Prostate and Urologic Cancers Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
BJU Int 111:589-95. 2013..In addition, competing risks analyses showed that although current smoking did not increase the risk of recurrence, it imparted a significant risk of dying compared with former and never smoking...
Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancerSusannah M Mourton
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, MRI-1026, New York, NY 10021, USA
Gynecol Oncol 99:608-14. 2005..Protective ileostomy is not always necessary and should be used selectively...
Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tractGanesh V Raj
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 175:2038-41; discussion 2041. 2006..However, the concordance with histological subclassification on prior cytology results ranges from 19% for adenocarcinoma to 60% for squamous cell carcinoma...
Bladder cancer imaging: an updateKelvin A Moses
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Curr Opin Urol 21:393-7. 2011..To present the recent advances in imaging for diagnosis, staging, and follow-up of bladder cancer...
Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approachesDaher C Chade
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 183:862-69. 2010..In this review we summarize the most comprehensive articles published on the oncological outcomes of laparoscopic assisted, robotic assisted and open radical cystectomy...
Importance of lymph node dissection in urologic cancersBernard H Bochner
Department of Urology, Memorial Sloan-Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, New York, NY, 10021 USA
Urol Oncol 22:197. 2004
A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancerMarta Sanchez-Carbayo
Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:3215-20. 2007..In this study, we aim to evaluate the SNP309 in bladder cancer and to link it to TP53 status...
Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatinEiji Kikuchi
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 10:1835-42. 2004..The purpose of this study was to investigate whether local overexpression of endostatin could serve to diminish tumor growth of bladder cancer in vivo...
Multimodal therapy for urologic cancersBernard H Bochner
Nat Clin Pract Urol 3:453. 2006
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patientsMartin G Friedrich
Departments of Urology, Clinical Pathology, and Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089-9176, USA
Clin Cancer Res 10:7457-65. 2004..Our results also indicate that some methylation markers, such as those in regions of RASSF1A and TNFRSF25, might be of limited use for detection because they are also methylated in normal bladder tissues...
